GD1 COST-UTILITY ANALYSIS OF «ON DEMAND» RABEPRAZOLE AND ESOMEPRAZOLE FOR SYMPTOMATIC GASTRO OESOPHAGEAL REFLUX DISEASE

Value in Health ◽

10.1016/s1098-3015(10)61575-6 ◽

2003 ◽

Vol 6 (6) ◽

pp. 613

Author(s):

DA Hughes ◽

D Dubois

Keyword(s):

Reflux Disease ◽

Cost Utility ◽

Cost Utility Analysis ◽

Oesophageal Reflux ◽

Utility Analysis ◽

On Demand ◽

Oesophageal Reflux Disease

Download Full-text

Cost–utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever

Blood Coagulation & Fibrinolysis ◽

10.1097/mbc.0000000000000280 ◽

2015 ◽

Vol 26 (4) ◽

pp. 403-407 ◽

Author(s):

Cho Naing ◽

Yong Poovorawan ◽

Joon Wah Mak ◽

Kyan Aung ◽

Pirom Kamolratankul

Keyword(s):

Factor Viia ◽

Cost Utility ◽

Cost Utility Analysis ◽

Dengue Haemorrhagic Fever ◽

Haemorrhagic Fever ◽

Utility Analysis ◽

On Demand ◽

Bleeding Episodes

Download Full-text

On-demand requirements of patients with endoscopy-negative gastro-oesophageal reflux disease: H2-blocker vs. proton pump inhibitor

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2008.03877.x ◽

2009 ◽

Vol 29 (2) ◽

pp. 207-212 ◽

Author(s):

P. JUUL-HANSEN ◽

A. RYDNING

Keyword(s):

Proton Pump Inhibitor ◽

Proton Pump ◽

Reflux Disease ◽

Oesophageal Reflux ◽

On Demand ◽

Oesophageal Reflux Disease ◽

Download Full-text

PSY57 - A COMPARISON BETWEEN ON DEMAND USAGE OF RFVIIA VS PROPHYLAXIS USE OF EMICIZUMAB IN HIGH TITER INHIBITORY HEMOPHILIA A PATIENTS IN IRAN; A COST UTILITY ANALYSIS

Value in Health ◽

10.1016/j.jval.2018.09.2633 ◽

2018 ◽

Vol 21 ◽

pp. S445

Author(s):

M. Seyedifar ◽

J. Khedmati ◽

P. Eshghi

Keyword(s):

Hemophilia A ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Download Full-text

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months

Alimentary Pharmacology & Therapeutics ◽

10.1046/j.1365-2036.2001.00943.x ◽

2001 ◽

Vol 15 (3) ◽

pp. 347-354 ◽

Author(s):

N. J. Talley ◽

K. Lauritsen ◽

H. Tunturi-Hihnala ◽

T. Lind ◽

B. Moum ◽

...

Keyword(s):

Reflux Disease ◽

Controlled Trial ◽

Symptom Control ◽

Oesophageal Reflux ◽

On Demand ◽

Oesophageal Reflux Disease

Download Full-text

On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease

Digestive and Liver Disease ◽

10.1016/s1590-8658(02)80259-6 ◽

2002 ◽

Vol 34 (12) ◽

pp. 870-877 ◽

Author(s):

F. Pace ◽

S. Pallotta ◽

G. Bianchi Porro

Keyword(s):

Proton Pump Inhibitor ◽

Proton Pump ◽

Reflux Disease ◽

Proton Pump Inhibitor Therapy ◽

Inhibitor Therapy ◽

Oesophageal Reflux ◽

On Demand ◽

Oesophageal Reflux Disease

Download Full-text

Su1016 - Cost-Utility Analysis of Potassium-Competitive Acid Blockerbased Therapeutic Strategy for Gastroesophageal Reflux Disease Compared with Proton-Pump Inhibitor-Based Strategy

Gastroenterology ◽

10.1016/s0016-5085(18)31774-8 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-455-S-456 ◽

Author(s):

Kazuhide Higuchi ◽

Akihito Uda ◽

Hisato Deguchi ◽

Kazuo Ueda ◽

Yasuhito Watanabe ◽

...

Keyword(s):

Gastroesophageal Reflux Disease ◽

Proton Pump Inhibitor ◽

Gastroesophageal Reflux ◽

Proton Pump ◽

Reflux Disease ◽

Therapeutic Strategy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis

Download Full-text

Long-term therapy of nizatidine (NZ) plus maalox dry granule (MDG) in patients with gastro-esophageal reflux disease (GERD): A cost-utility analysis in Japan

Gastroenterology ◽

10.1016/s0016-5085(98)81158-x ◽

1998 ◽

Vol 114 ◽

pp. A284

Author(s):

H. Shibata ◽

R. Shibata ◽

H. Tanaka ◽

R. Harasawa ◽

T. Miwa

Keyword(s):

Reflux Disease ◽

Cost Utility ◽

Cost Utility Analysis ◽

Term Therapy ◽

Utility Analysis ◽

Esophageal Reflux ◽

Long Term Therapy

Download Full-text

PSY17 Cost-Utility Analysis of Immune Tolerance Induction (ITI) Therapy Versus On-Demand Treatment With Recombinant FVII (rFVIIa) for Hemophilia A With High Titer Inhibitors in Iran

Value in Health ◽

10.1016/j.jval.2012.08.461 ◽

2012 ◽

Vol 15 (7) ◽

pp. A680

Author(s):

A. Imani ◽

H. Rasekh ◽

M. Golestani

Keyword(s):

Immune Tolerance ◽

Hemophilia A ◽

Tolerance Induction ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Immune Tolerance Induction ◽

Download Full-text

Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia

PharmacoEconomics ◽

10.2165/00019053-200220110-00005 ◽

2002 ◽

Vol 20 (11) ◽

pp. 759-774 ◽

Author(s):

Alexander H. Miners ◽

Caroline A. Sabin ◽

Keith H. Tolley ◽

Christine A. Lee

Keyword(s):

Primary Prophylaxis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Severe Haemophilia ◽

Utility Analysis ◽

On Demand ◽

Versus Treatment

Download Full-text

Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A

Haemophilia ◽

10.1111/j.1365-2516.2008.01664.x ◽

2008 ◽

Vol 14 (4) ◽

pp. 743-752 ◽

Author(s):

N. RISEBROUGH ◽

P. OH ◽

V. BLANCHETTE ◽

J. CURTIN ◽

J. HITZLER ◽

...

Keyword(s):

Young Children ◽

Primary Prophylaxis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Haemophilia A ◽

Severe Haemophilia ◽

Utility Analysis ◽

Download Full-text